# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of c...
Oppenheimer analyst Francois Brisebois initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Outperform rating ...
Truist Securities analyst Joon Lee maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $60 price target.
HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...
Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimat...
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Buy rati...
Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and lowers the price target from...
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of c...